Idorsia’s stakeholders value excellence in governance. We aim to be transparent, applying the highest standards of integrity across the company. Our Legal & Compliance function seeks to drive a culture of integrity, with the following priorities:
- communicate clearly to employees
- focus on important compliance risk areas
- improve compliance behavior through training and support
- ensure that employees can raise concerns and that these are properly addressed
- ensure fair and objective investigations of potential policy breaches
An example of best practice in governance is our Code of Business Conduct, which underpins our commitment to integrity and sets out fundamental rules for interacting with others as we drive our business forward. Supporting policies, standard operating procedures and guidelines provide more detail on how our high-level commitments are to be applied in practice. All Idorsia employees have undergone mandatory training to ensure compliance with the Code.
The Idorsia code of conduct is at the foundation of our corporate culture and defines the core principles and ethical standards by which we create value in our company. It is the responsibility of every Idorsia employee to be familiar with, and to comply with, our code of conduct.
We are proactive in establishing policies and practices that support strong corporate governance and transparency. These policies and practices are continually reviewed and enhanced as appropriate.
Privacy & Data Security
Idorsia understands the importance of protecting personal information and applying the highest ethical and regulatory standards. We are committed to respecting our stakeholders’ privacy and safeguarding their personal information. Idorsia’s data protection policy covers data on patients, healthcare professionals, customers, suppliers and employees.
To ensure the integrity and privacy of the personal and health-related information provided to us, we use state-of-the-art information security programs, focusing on protection of sensitive information and detection of unauthorized access.
Corruption & Bribery
Full compliance with applicable laws in all the regions where Idorsia operates is crucial to our success.
Idorsia’s position is clearly stated in our Anti-Corruption and Anti-Bribery Policy: We take a zero‑tolerance approach to bribery and corruption and are committed to acting professionally in all our business dealings and relationships wherever we operate. We implement and enforce effective systems to counter bribery. We will uphold all laws relevant to countering bribery and corruption in all the jurisdictions in which we operate. All Idorsia employees are required to complete training on this policy.
Labor & Human Rights
Idorsia respects the rights of its employees as set out in the Universal Declaration of Human Rights, and we fully comply with all relevant laws, rules and regulations governing labor, employment and the employment relationship in all the countries where we operate.
We respect the right of all employees to join a legally recognized employee association, and we comply with all laws relating to employee representation. We strive to maintain an open dialogue with all our employees and their representatives.
Due to the nature of our business and the location of our operations, the risk of child or forced labor is minimal. We do, however, remain vigilant for unexpected issues that may arise – not only in our own operations but also in relation to our procurement practices. Our expectations regarding working conditions, human rights protection, business ethics, legal compliance and environmental protection are set out in our Supplier Code of Conduct.
We strive to maintain the highest ethical, scientific, and clinical standards in all our research activities and to comply with all national and international standards. Idorsia regularly reviews its research policies to align them with its corporate values and goals, and with the evolving values and goals of its stakeholders.
Regulatory authorities around the world require pharmaceutical companies to test all new drugs before they are launched, and there is no alternative to including some animal testing as part of this process. It is essential both for scientific reasons and to safeguard the volunteers and patients who take part in subsequent clinical trials.
As a fundamental principle we support the ‘three R’s’ in relation to animal testing:
Refinement – Alleviate or minimize impacts to animals by reducing potentially painful or invasive procedures, whenever possible
Reduction – Use the absolute minimum number of animals required to obtain valid results in each study
Replacement – Always look for alternative, non-animal-based research methods where possible
The number of animals used in drug development has dropped dramatically over the past three decades as a result of industry initiatives like this. Idorsia has a strong policy on the care, welfare and treatment of animals and we conduct regular audits to make sure that our expectations are being met, whether the studies are being conducted in-house or outsourced.
In addition, we ensure that the use and care of all laboratory animals meets or exceeds relevant local, national and international regulations. Our programs and facilities are subject to unannounced regulatory review and inspections. For sponsored work at contract research organizations, our animal welfare oversight activities include regular on-site evaluations by our veterinary staff. Idorsia will never used great apes (gorillas, chimpanzees, orangutans and bonobos) in its research, and this is explicitly prohibited in our animal welfare policy.
Clinical Trials Transparency
Clinical trials are essential to the development of innovative medicines. Idorsia is committed to the highest standards of quality and ethical conduct in all our clinical research. Our trials are performed in accordance with internationally accepted guidelines, and protocols are evaluated by independent review boards and ethics committees prior to study initiation. We are also dedicated to improving public health through responsible clinical trial data transparency which – as well as complying with applicable regulations – respects our proprietary information and patients’ privacy. In addition to our existing clinical trial disclosure activities, we are committed to implementing the EFPIA/PhRMA Principles for Responsible Clinical Trial Data Sharing.